Company intelligence / Profile preview

Nosopharm

Overview

Nosopharm is developing novel antimicrobial drugs with their lead candidate NOSO-502 in preclinical stage for Gram-Negative Bacterial Infections

4 assets

Preclinical

3 more assets in the full pipeline.

Part of the Gram-negative Antibacterial Engine (pan-European Project)

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Nosopharm.